US priority review status for oral MS drug Cladribine
US priority review status for oral MS drug Cladribine
German pharmaceutical and chemicals company Merck KGaA has announced that the U.S. Food and Drug Administration accepted a new drug application for its oral multiple sclerosis treatment Cladribine with a priority review designation, after Merck's initial submission was rejected last fall.
Priority review status is applied to drugs that have the potential to provide significant advances in treatment and means the FDA will complete its review in six months rather than the usual 10. Merck expects a decision in the fourth quarter....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1535 Views
-
Last post by jimmylegs
-
- 3 Replies
- 1502 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1825 Views
-
Last post by frodo
-
- 0 Replies
- 1638 Views
-
Last post by frodo
-
- 0 Replies
- 1965 Views
-
Last post by NHE
-
- 0 Replies
- 1171 Views
-
Last post by NHE
-
- 1 Replies
- 1606 Views
-
Last post by frodo
-
- 0 Replies
- 1167 Views
-
Last post by frodo
-
- 0 Replies
- 1735 Views
-
Last post by frodo